CN101659941A - 一种永生化人肝细胞系及其制备方法和用途 - Google Patents
一种永生化人肝细胞系及其制备方法和用途 Download PDFInfo
- Publication number
- CN101659941A CN101659941A CN200910091343A CN200910091343A CN101659941A CN 101659941 A CN101659941 A CN 101659941A CN 200910091343 A CN200910091343 A CN 200910091343A CN 200910091343 A CN200910091343 A CN 200910091343A CN 101659941 A CN101659941 A CN 101659941A
- Authority
- CN
- China
- Prior art keywords
- liver cell
- cell line
- human liver
- immortalized human
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000005229 liver cell Anatomy 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 69
- 210000004185 liver Anatomy 0.000 claims abstract description 48
- 206010019663 Hepatic failure Diseases 0.000 claims abstract description 23
- 208000007903 liver failure Diseases 0.000 claims abstract description 23
- 231100000835 liver failure Toxicity 0.000 claims abstract description 23
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 241000700605 Viruses Species 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000010367 cloning Methods 0.000 claims abstract description 3
- 210000003494 hepatocyte Anatomy 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 19
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 13
- 108010088751 Albumins Proteins 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 11
- 102000005396 glutamine synthetase Human genes 0.000 claims description 10
- 108020002326 glutamine synthetase Proteins 0.000 claims description 10
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 9
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 108010014173 Factor X Proteins 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000001890 transfection Methods 0.000 claims description 8
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 102000004195 Isomerases Human genes 0.000 claims description 3
- 108090000769 Isomerases Proteins 0.000 claims description 3
- HDYANYHVCAPMJV-LXQIFKJMSA-K UDP-alpha-D-glucuronate(3-) Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP([O-])(=O)OP([O-])(=O)O[C@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O HDYANYHVCAPMJV-LXQIFKJMSA-K 0.000 claims description 3
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 claims description 3
- 230000036983 biotransformation Effects 0.000 claims description 3
- 230000007102 metabolic function Effects 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000008676 import Effects 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 108010017842 Telomerase Proteins 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 102100026214 Indian hedgehog protein Human genes 0.000 description 32
- 230000006870 function Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 102100027211 Albumin Human genes 0.000 description 11
- 238000001784 detoxification Methods 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 8
- 108010070675 Glutathione transferase Proteins 0.000 description 7
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical class OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 208000007788 Acute Liver Failure Diseases 0.000 description 6
- 206010000804 Acute hepatic failure Diseases 0.000 description 6
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101150066002 GFP gene Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 2
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 2
- 102000007648 Glutathione S-Transferase pi Human genes 0.000 description 2
- 108010007355 Glutathione S-Transferase pi Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 2
- 102100033782 UDP-galactose translocator Human genes 0.000 description 2
- 101710148271 UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 description 2
- 102100029151 UDP-glucuronosyltransferase 1A10 Human genes 0.000 description 2
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100030176 Muscular LMNA-interacting protein Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101000965899 Simian virus 40 Large T antigen Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010015799 bilirubin glucuronoside glucuronosyltransferase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 244000059546 zoonotic virus Species 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100913432A CN101659941B (zh) | 2009-08-18 | 2009-08-18 | 一种永生化人肝细胞系及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100913432A CN101659941B (zh) | 2009-08-18 | 2009-08-18 | 一种永生化人肝细胞系及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101659941A true CN101659941A (zh) | 2010-03-03 |
CN101659941B CN101659941B (zh) | 2011-08-31 |
Family
ID=41788195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100913432A Active CN101659941B (zh) | 2009-08-18 | 2009-08-18 | 一种永生化人肝细胞系及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101659941B (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104419669A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 重组sv40基因构建克氏综合征细胞模型及其细胞库 |
CN104419723A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40LT和hTERT基因重组构建T淋巴细胞模型及其细胞库 |
CN104419665A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40lt介导唐氏综合征细胞模型及其细胞库的构建 |
CN104419680A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 导入SV40LT和hTERT重组基因构建神经管缺陷细胞模型及其细胞库 |
CN104419668A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40lt重组构建染色体缺失猫叫综合征细胞模型及其细胞库 |
CN104419664A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40T基因诱导构建Turner综合征细胞模型及其细胞库 |
CN105505883A (zh) * | 2016-01-12 | 2016-04-20 | 河南师范大学 | 一种大鼠原代肝细胞的优化培养方法 |
CN109022416A (zh) * | 2018-06-15 | 2018-12-18 | 翁炳焕 | Hbv-dna检测单克隆质控参考株的制备 |
CN109207429A (zh) * | 2018-05-04 | 2019-01-15 | 窦科峰 | 永生化的α-1,3-半乳糖转移酶基因敲除猪肝细胞系及其制备方法和应用 |
CN109355262A (zh) * | 2018-06-13 | 2019-02-19 | 浙江生创精准医疗科技有限公司 | 永生化宫血干细胞系 |
CN109477119A (zh) * | 2016-02-04 | 2019-03-15 | 斯比根公司 | 表达肝细胞生长因子的间充质干细胞及其用途 |
CN110438157A (zh) * | 2019-08-05 | 2019-11-12 | 上海赛立维生物科技有限公司 | 肝前体样细胞系、构建方法以及在生物人工肝领域的应用 |
CN113583940A (zh) * | 2021-08-31 | 2021-11-02 | 成都以邦医药科技有限公司 | 一种肝卵圆细胞永生化培养基及其制备方法和应用 |
-
2009
- 2009-08-18 CN CN2009100913432A patent/CN101659941B/zh active Active
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104419669A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 重组sv40基因构建克氏综合征细胞模型及其细胞库 |
CN104419723A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40LT和hTERT基因重组构建T淋巴细胞模型及其细胞库 |
CN104419665A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40lt介导唐氏综合征细胞模型及其细胞库的构建 |
CN104419680A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 导入SV40LT和hTERT重组基因构建神经管缺陷细胞模型及其细胞库 |
CN104419668A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40lt重组构建染色体缺失猫叫综合征细胞模型及其细胞库 |
CN104419664A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40T基因诱导构建Turner综合征细胞模型及其细胞库 |
CN105505883A (zh) * | 2016-01-12 | 2016-04-20 | 河南师范大学 | 一种大鼠原代肝细胞的优化培养方法 |
CN109477119A (zh) * | 2016-02-04 | 2019-03-15 | 斯比根公司 | 表达肝细胞生长因子的间充质干细胞及其用途 |
CN109207429A (zh) * | 2018-05-04 | 2019-01-15 | 窦科峰 | 永生化的α-1,3-半乳糖转移酶基因敲除猪肝细胞系及其制备方法和应用 |
CN109355262A (zh) * | 2018-06-13 | 2019-02-19 | 浙江生创精准医疗科技有限公司 | 永生化宫血干细胞系 |
CN109022416A (zh) * | 2018-06-15 | 2018-12-18 | 翁炳焕 | Hbv-dna检测单克隆质控参考株的制备 |
CN110438157A (zh) * | 2019-08-05 | 2019-11-12 | 上海赛立维生物科技有限公司 | 肝前体样细胞系、构建方法以及在生物人工肝领域的应用 |
CN113583940A (zh) * | 2021-08-31 | 2021-11-02 | 成都以邦医药科技有限公司 | 一种肝卵圆细胞永生化培养基及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101659941B (zh) | 2011-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101659941B (zh) | 一种永生化人肝细胞系及其制备方法和用途 | |
Boynton et al. | Different calcium requirements for proliferation of conditionally and unconditionally tumorigenic mouse cells. | |
CN111454878B (zh) | 类器官病毒感染模型的构建方法和应用 | |
CN106801032B (zh) | 人羊膜上皮干细胞库的构建方法 | |
CN110438157B (zh) | 肝前体样细胞系、构建方法以及在生物人工肝领域的应用 | |
CN107118552B (zh) | 一种基于明胶和氨基酸的复合膜及在膜上培养角膜缘干细胞的方法 | |
Pan et al. | Establishment and characterization of immortalized porcine hepatocytes for the study of hepatocyte xenotransplantation | |
CN107384949B (zh) | 表达GPC3嵌合抗原受体的iNKT细胞及制备、应用 | |
US20190345441A1 (en) | Preparation and application of immortalized alpha-1,3-galactosyltransferase gene knockout pig hepatocyte cell line | |
CN101497872B (zh) | 诱导人胚胎干细胞定向分化为肝细胞的专用培养基 | |
CN109082401A (zh) | 一种羊膜上皮干细胞诱导分化为功能性肝细胞的方法及其应用 | |
CN102286535B (zh) | 一种成纤维细胞转分化为肝干细胞的方法 | |
CN108823148A (zh) | 一种脂肪间充质干细胞诱导分化为肝脏样细胞的方法 | |
CN103275933B (zh) | 一种人肝癌细胞系hlcz01及其应用 | |
WO2008049281A1 (fr) | Procédé de construction d'une construction de génie tissulaire hépatique et construction de génie tissulaire hépatique | |
CN1884494B (zh) | 诱导人胚胎干细胞向肝脏细胞分化的方法及其专用培养基 | |
CN103396985A (zh) | 诱导人脐带间充质干细胞分化为肝细胞的方法与应用 | |
CN105483089A (zh) | 一种永生化仔猪口腔黏膜上皮细胞系及其建立方法和应用 | |
CN113789350A (zh) | 哺乳类食管鳞状上皮永生化细胞系的构建方法、构建的细胞系及其类器官 | |
CN103881908A (zh) | 一种用于细胞共培养的生物反应器系统 | |
CN110106144B (zh) | 一种诱导造血干细胞向前t系细胞分化的方法和试剂盒 | |
CN102181399A (zh) | 一种cd133高表达鼠肝肿瘤细胞系及制备方法 | |
JP6418761B2 (ja) | 肝炎組織体、肝炎ウイルスの感染方法、肝炎組織体の製造方法、肝炎ウイルスの増殖方法、肝炎ワクチンの製造方法、スクリーニング方法、及びキット | |
Chen et al. | Bone Morphogenetic Protein-2 regulates in vitro osteogenic differentiation of mouse adipose derived stem cells | |
Coetzee et al. | Transmission of jaagsiekte (ovine pulmonary adenomatosis) by means of a permanent epithelial cell line established from affected lungs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU ZHONGRONG INDUSTRY CO., LTD. Free format text: FORMER OWNER: CHINA-JAPAN FRIENDSHIP HOSPITAL Effective date: 20130922 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100037 CHAOYANG, BEIJING TO: 215007 SUZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130922 Address after: Wuzhong Economic Development Zone of Suzhou City, Jiangsu province 215007 Po Village Patentee after: Suzhou Zhongrong Industrial Co.,Ltd. Address before: 100037, 2, Sakura East Street, Beijing, Chaoyang District Patentee before: China-Japan Friendship Hospital |
|
ASS | Succession or assignment of patent right |
Owner name: SUZHOU RUILAI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SUZHOU ZHONGRONG INDUSTRY CO., LTD. Effective date: 20150727 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150727 Address after: 215103, Suzhou, Jiangsu, Wuzhong District Jing Jing Street, Swan Road, No. 2011, 10 Patentee after: SUZHOU RUI LAI BIOTECHNOLOGY Co.,Ltd. Address before: Wuzhong Economic Development Zone of Suzhou City, Jiangsu province 215007 Po Village Patentee before: Suzhou Zhongrong Industrial Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A immortalized human liver cell line and its preparation method and application Granted publication date: 20110831 Pledgee: Bank of Jiangsu Co.,Ltd. Suzhou Branch Pledgor: SUZHOU RUI LAI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980008917 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |